Signal from the log
CORXEL Pharmaceuticals
287 M$ · Series D and later · United States · Biotech
Société biopharmaceutique installée dans le New Jersey et fondée à Shanghai, qui développe CX11, un agoniste du récepteur GLP-1 administré en comprimé contre l'obésité et les maladies cardiométaboliques. Le tour finance la phase 2 aux États-Unis et prépare la phase 3, sur le pari d'une alternative orale aux injections.
Verified
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 287 M$
- Stage
- Series D and later
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by RTW Investments , TCG Crossover , RA Capital Management , with SR One Capital Management , HBM Healthcare Investments , SymBiosis
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.